<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0404233483
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1993
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        KLACID 250MG TAB
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        CLARITHROMYCIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        250
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        14
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        60.4
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="ABBVIE SRL" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            ABBVIE SRL
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Abbott Laboratories GmbH
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J01FA09
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Each KLACID contains 250 mg of the active ingredient clarithromycin. KLACID tablet belongs to a group of medicines called macrolide antibiotics.</p><p>Antibiotics stop the growth of bacteria (bugs) which cause infections. KLACID tablets are used to treat infections such as:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Upper respiratory tract infections for example, sinusitis, tonsillitis and pharyngitis.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Lower respiratory tract infections for example, acute and chronic bronchitis and pneumonia.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Skin and soft tissue infections of mild to moderate severity for example, impetigo, erysipelas, folliculitis, cellulitis, furunculosis, and infected wounds.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Clarithromycin is appropriate for initial therapy in community acquired respiratory infections and has been shown to be active in-vitro against common and atypical respiratory pathogens.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Clarithromycin in the presence of acid suppression effected by omeprazole or lansoprazole is indicated for the eradication of H.pylori in patients with duodenal ulcers.</p><p>&nbsp;</p><p>KLACID Tablets are indicated in adults and children 12 years and older.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take KLACID tablets if you;</strong></p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; know that you are <strong>a</strong><strong>llergic </strong>to clarithromycin, other macrolide antibiotics such as erythromycin or azithromycin, or any of the other ingredients in the tablets.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are taking medicines called ergot alkaloid tablets (e.g. ergotamine or dihydroergotamine) or use ergotamine inhalers for migraine.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are taking medicines called terfenadine or astemizole (widely taken for hay fever or allergies) or cisapride or domperidone (for stomach disorders) or pimozide (for mental health problems) as combining these drugs can sometimes cause serious disturbances in heart rhythm. Consult your doctor for advice on alternative medicines.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are taking other medicines which are known to cause serious disturbances in heart rhythm.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are taking lovastatin or simvastatin (HMG-CoA reductase inhibitors, commonly known as statins, used to lower levels of cholesterol (a type of fat) in the blood).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are taking oral midazolam (a sedative).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have abnormally low levels of potassium in your blood (hypokalaemia).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have <strong>severe </strong>liver disease with kidney disease.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; or someone in your family has a history of heart rhythm disorders (ventricular cardiac arrhythmia, including torsades de pointes) or abnormality of electrocardiogram (ECG, electrical recording of the heart) called &quot;long QT syndrome&quot;.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are taking medicines called ticagrelor or ranolazine (for heart attack, chest pain or angina)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are taking colchicine (usually taken for gout)</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor or pharmacist before taking KLACID tablets:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have heart problems (e.g. heart disease, heart failure, an unusually slow heart rate, or abnormally low levels of magnesium in the blood (hypomagnesaemia))</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have any liver or kidney problems</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have, or are prone to, fungal infections (e.g. thrush)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are pregnant or breast feeding</p><p>&nbsp;</p><p><strong>KLACID tablets are not suitable for use in children under 12 years of age. </strong></p><p>&nbsp;</p><p><strong>Other medicines and KLACID Tablets</strong></p><p>&nbsp;</p><p>You should not take Klacid tablets if you are taking any of the medicines listed in the section above &ldquo;Do not take Klacid tablets if you;&rdquo;</p><p>&nbsp;</p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines as your dose may need to be changed or you may need to have regular tests performed:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; digoxin, quinidine or disopyramide (for heart problems)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ibrutinib (for cancer treatment)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; warfarin, or any other anticoagulant (for blood thinning)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; carbamazepine, valproate, phenobarbital or phenytoin (for epilepsy)</p><p>atorvastatin, rosuvastatin &nbsp;(HMG-CoA reductase inhibitors, commonly known as statins, and used to lower levels of cholesterol (a type of fat) in the blood). Statins can cause rhabdomyolosis (a condition which causes the breakdown of muscle tissue</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; which can result in kidney damage) and signs of myopathy (muscle pain or muscle weakness) should be monitored.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nateglinide, pioglitazone, repaglinide, rosiglitazone or insulin (used to lower blood glucose levels)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; gliclazide or glimepiride (sulphonylureas used in the treatment of type II diabetes)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; theophylline (used in patients with breathing difficulties such as asthma)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; triazolam, alprazolam or intravenous or oromucosal midazolam (sedatives)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cilostazol (for poor circulation)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; methadone (used in the treatment of opioid addiction)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; methylprednisolone (a corticosteroid)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vinblastine (for treatment of cancer)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ciclosporin, sirolimus and tacrolimus (immune suppressants)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; etravirine, &nbsp;efavirenz, nevirapine, ritonavir, zidovudine, atazanavir, saquinavir (anti-viral drugs used in the treatment of HIV)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rifabutin, rifampicin, rifapentine, fluconazole, itraconazole (used in the treatment of certain bacterial infections)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tolterodine (for overactive bladder)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; verapamil, amlodipine, diltiazem (for high blood pressure)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sildenafil, vardenafil and tadalafil (for impotence in adult males or for use in pulmonary arterial hypertension (high blood pressure in the blood vessels of the lung))</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; St John&rsquo;s Wort (a herbal product used to treat depression)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; quetiapine or other antipsychotic medicines.</p><p>&bull;&nbsp; other macrolide medicines</p><p>&bull;&nbsp; lincomycin and clindamycin (lincosamides &ndash; a type of antibiotic)</p><p>Please tell your doctor if you are taking oral contraceptive pills and diarrhoea or vomiting occurs, as you may need to take extra contraceptive precautions such as using a condom.</p><p><strong>P</strong><strong>r</strong><strong>e</strong><strong>gnancy and breast-feeding</strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist before taking this medicine as the safety of KLACID tablets in pregnancy and breast-feeding is not known</p><p>&nbsp;</p><p><strong>Driving and Using Machines:</strong></p><p>KLACID tablets may make you feel dizzy or drowsy. If they affect you in this way do not drive, operate machinery or do anything that requires you to be alert.</p><p>&nbsp;</p><p>Klacid tablets contains less than 1 mmol sodium (23 mg) per dosage unit, that is to say essentially &lsquo;sodium-free&rsquo;.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not give these tablets to children under 12 years. Your doctor will prescribe another suitable medicine for your child.</p><p>&nbsp;</p><p>Always take KLACID tablets exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure. The recommended dose is;</p><p><strong>F</strong><strong>or chest infections, throat or sinus infections and skin and soft tissue infections</strong>: Usual dose of KLACID tablets for adults and children over 12 years is 250 mg twice daily for 6 to 14 days, e.g. one 250 mg tablet in the morning and one in the early evening. Your doctor may increase the dose to 500 mg twice daily in severe infections.</p><p>KLACID tablets should be swallowed with at least half a glass of water.</p><p>&nbsp;</p><p><strong>F</strong><strong>or the treatment of <em>Helicobacter pylori </em>infection associated with duodenal ulcers: </strong></p><p>There are a number of effective treatment combinations available to treat <em>Helicobacter pylori </em>in which KLACID tablets are taken together with one or two other drugs.</p><p>These combinations include the following and are usually taken for 6 to 14 days:</p><p>a) One KLACID 500 mg tablet taken twice a day together with amoxycillin, 1000 mg taken twice a day plus lansoprazole, 30 mg twice a day.</p><p>b) One KLACID 500 mg tablet taken twice a day together with metronidazole, 400 mg taken twice a day plus lansoprazole, 30 mg twice a day.</p><p>c) One KLACID 500 mg tablet taken twice a day together with amoxycillin, 1000 mg taken twice a day or metronidazole, 400 mg taken twice a day plus omeprazole, 40 mg a day.</p><p>d) One KLACID 500 mg tablet taken twice a day together with amoxycillin, 1000 mg taken twice a day plus omeprazole, 20 mg taken once a day.</p><p>&nbsp;</p><p>The treatment combination that you receive may differ slightly from the above. Your doctor will decide which treatment combination is the most suitable for you. If you are unsure which tablets you should be taking or how long you should be taking them for, please consult your doctor for advice.</p><p><strong>If you take more KLACID tablets than you should</strong></p><p>If you accidentally take more KLACID tablets in one day than your doctor has told you to, or if a child accidentally swallows some tablets, contact your doctor or nearest hospital emergency department immediately. An overdose of KLACID tablets is likely to cause vomiting and stomach pains.</p><p>&nbsp;</p><p><strong>If you forget to take KLACID tablets</strong></p><p>If you forget to take an KLACID tablet, take one as soon as you remember. Do not take more tablets in one day than your doctor has told you to.</p><p>&nbsp;</p><p><strong>If you stop taking KLACID tablets</strong></p><p>Do not stop taking KLACID tablets, even if you feel better. It is important to take the tablets for as long as the doctor has told you to, otherwise the problem might come back.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, KLACID tablets can cause side effects although not everybody gets them.</p><p>If you suffer from any of the following at any time during your treatment STOP TAKING your tablets and contact your doctor immediately:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe or prolonged diarrhoea, which may have blood or mucus in it. &nbsp;Diarrhoea may occur over two months after treatment with clarithromycin, in which case you should still contact your doctor.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a rash, difficulty breathing, fainting or swelling of the face, tongue, lips, eyes and throat. This is a sign that you may have developed an allergic reaction.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; yellowing of the skin (jaundice), skin irritation, pale stools, dark urine, tender abdomen or loss of appetite. These may be signs that your liver may have inflammation and not be working properly.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe skin reactions such as painful blistering of the skin, mouth, lips, eyes and genitals (symptoms of a rare allergic reaction called Stevens-Johnson syndrome/toxic epidermal necrolysis).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a red, scaly rash with bumps under the skin and blisters (symptoms of exanthematous pustulosis). The frequency of this side effect is not known (cannot be estimated from the available data).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rare allergic skin reactions which cause severe illness with ulceration of the mouth, lips and skin which causes severe illness with rash, fever and inflammation of internal organs (DRESS).</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle pain or weakness known as rhabdomyolysis (a condition which causes the breakdown of muscle tissue which can result in kidney damage).</p><p>Other side effects:</p><p>&nbsp;</p><p>Common side effects (may affect up to 1 in 10 people) include;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; difficulty sleeping</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; changes in sense of taste</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; widening of blood vessels</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stomach problems such as feeling sick, vomiting, stomach pain, indigestion, diarrhoea</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased sweating</p><p>&nbsp;</p><p>Uncommon side effects (may include up to 1 in 1 00 people) include:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high temperature</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling, redness or itchiness of the skin</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; oral or vaginal &#39;thrush&#39; (a fungal infection)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the stomach and intestines</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decrease of the levels of blood platelets (blood platelets help stop bleeding)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decrease in white blood cells (leukopenia)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decrease in neutrophils (neutropenia)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stiffness</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chills</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increase of eosinophils (white blood cells involved in immunity)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; exaggerated immune response to a foreign agent</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; lack or loss of appetite</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; anxiety, nervousness</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; drowsiness, tiredness, dizziness or shaking</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; involuntary muscle movements</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vertigo</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ringing in the ears or hearing loss</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chest pain or changes in heart rhythm such as palpitations or an irregular heartbeat</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; asthma: lung disease associated with tightening of air passages, making breathing difficult</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nose bleed</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blood clot that causes sudden blockage in a lung artery (pulmonary embolism)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the lining of the gullet (oesophagus) and lining of the stomach anal pain</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bloating, constipation, wind, burping</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dry mouth</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; situation where the bile (fluid made by the liver and stored in the gallbladder) cannot flow from the gallbladder to the duodenum (cholestasis)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the skin characterized by the presence of the bullae which are filled with fluid, itchy and painful rash</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle spasms, muscle pain or loss of muscle tissue. If your child suffers from myasthenia gravis (a condition in which the muscles become weak and tire easily), clarithromycin may worsen these symptoms.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; raised abnormal kidney and liver function blood test and raised blood tests</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling weak, tired and having no energy</p><p>&nbsp;</p><p>Not known side effects (frequency cannot be estimated from the available data):</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the colon</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bacterial infection of the outer layers of the skin</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reduction in the level of certain blood cells (which can make infections more likely or increase the risk of bruising or bleeding)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; confusion, loss of bearings, hallucinations (seeing things), change in sense of reality or panicking, depression, abnormal dreams or nightmares and mania (feeling of elation or over-excitement)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; convulsion (fits)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; paraesthesia, more commonly known as &#39;pins and needles&#39;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; loss of taste or smell or inability to smell properly</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; type of heart rhythm disorder (Torsade de pointes, ventricular tachycardia)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; loss of blood (haemorrhage)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the pancreas</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; discolouration of the tongue or teeth</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; acne</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; change in the levels of products produced by the kidney, inflammation of the kidney or an inability of the kidney to function properly (you may notice tiredness, swelling or puffiness in the face, abdomen, thighs or ankles or problems with urination)</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>Reporting side effects</strong></p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. By reporting side effects you can help provide more information on the safety of this medicine.</p><p><strong>To report any side effect(s):</strong></p><p>o <strong>-National Pharmacovigilance Center (NPC)</strong></p><p><strong>o Fax: +966-11-205-7662</strong></p><p><strong>o SFDA Call Center: 19999</strong></p><p><strong>o E-mail: npc.drug@sfda.gov.sa</strong></p><p><strong>o Website: https://ade.sfda.gov.sa</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>K</strong><strong>e</strong><strong>e</strong><strong>p</strong><strong> this medicine </strong><strong>out of the sight and reach of children</strong></p><p><strong>Shelf life: 3 years </strong></p><p>Do not use these tablets after their use-by (exp) date that is printed on the box and indented on the blister strip.</p><p>Store below 25&deg;C.</p><p>Keep these tablets in a dry, safe place, protected from light.</p><p>Do not throw away any medicines via wastewater or household water. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What KLACID tablets contain</strong></p><p>Each KLACID tablet contains 250 mg of the active ingredient clarithromycin.</p><p>The other ingredients are; quinolone yellow (E104 aluminium lake), sodium croscarmellose, microcrystalline cellulose, silicon dioxide, povidone, stearic acid, magnesium stearate, talc, hypromellose, propylene glycol, sorbitan monooleate, titanium dioxide, vanillin, Hydroxypropylcellulose and sorbic acid</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                KLACID 250 mg tablets are yellow, oval and plain or marked with “a”.
KLACID 250 mg tablets are available as a single calendar packs containing 14 tablets

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder:</strong></p><p>Abbott Laboratoreis Gmbh, Hannover, Germany</p><p>&nbsp;</p><p><strong>Manufacturer</strong></p><p>AbbVie S.r.l, I- 04011 Campoverde di Aprilia, Italy</p><p>&nbsp;</p><p><strong>Packaged by</strong></p><p>Riyadh Pharma</p><p>Medical and cosmotic products Co .ltd</p><p>Riyadh &ndash; Saudi Arabia</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                May 2021
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي كل قرص من كلاسيد أقراص على 250 ملغم من المادة الفعالة كلاريثرومايسين التي تنتمي إلى مجموعة من المضادات الحيوية تسمى ماكروليد المضادات الحيوية الماكروليدية.</p><p dir="RTL">تعمل المضادات الحيوية على وقف نمو البكتيريا (الميكروبات) التي تسبب العدوى. تستخدم أقراص كلاسيد لعلاج <s>الالتهابات</s> حالات العدوى مثل:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى الجهاز التنفسي العلوي مثل التهاب الجيوب الأنفية، التهاب اللوزتين، والتهاب الحلق.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى الجهاز التنفسي السفلي مثل التهاب الشعب الحاد أو المزمن والتهاب الرئة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العدوى الخفيفة أو متوسطة الخطورة في الجلد والأنسجة الرخوة، مثل الحصف، الحمرة، التهاب الأجربة، والتهاب النسيج الخلوي الرخو تحت الجلد، الدمامل، والجروح المتقيحة.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُعتبر كلاريثروميسين مناسبًا للعلاج الأولي في حالات التهابات الجهاز التنفسي المكتسبة من المجتمع وقد ثبت أنه فعال في المختبر ضد مسببات الأمراض التنفسية الشائعة وغير النمطيّة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;يوصف كلاريثروميسين كذلك عند وجود تثبيط لحمض المعدة الناجم عن استخدام أوميبرازول أو لانسوبرازول &nbsp;للقضاء على الملوية البوابية لدى المرضى الذين يعانون من القرحة الإثنى عشرية.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">أقراص كلاسيد مخصصة للبالغين والأطفال من سن 12 عام فأكبر.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تستعمل كلاسيد إذا كنت:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعرف أن لديك حساسية كلاريثرومايسين، والمضادات الحيوية الأخرى التي تنتمي إلى مجموعة ماكروليد مثل إريثروميسين أو أزيثروميسين، أو نحو أي من المكونات الأخرى الموجودة في الأقراص.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تتناول أدوية تسمى أقراص قلويدات الإرغوت (مثل الإرغوتامين أو دايهيدروإرغوتامين) أو تستعمل بخاخات الإرغوتامين بالاستنشاق لعلاج الصداع النصفي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تتناول أدوية تسمى ترفينادين أو أستيميزول (تؤخذ على نطاق واسع لحمى الكلأ أو الحساسية) أو سيسابريد أو دومبيريدون (لاضطرابات المعدة) أو بيموزيد (لمشاكل الصحة النفسية) حيث إن تناول هذه الأدوية معاً يمكن أن يسبب أحياناً اضطرابات خطيرة في &nbsp;نظْم القلب. استشر طبيبك للحصول على المشورة بشأن تناول الأدوية البديلة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تتناول أدوية أخرى من المعروف أنها تسبب اضطرابات خطيرة في &nbsp;نظْم القلب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تتناول لوفاستاتين أو سيمفاستاتين (مثبطات&nbsp;مختزلة الإنزيم HMG-CoA المعروفة باسم الستاتينات، والتي تُستخدم لخفض مستويات الكولسترول (نوع من الدهون) في الدم).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تتناول ميدازولام عن طريق الفم (مهدئ).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعاني من انخفاض مستويات البوتاسيوم في الدم بشكل غير طبيعي (نقص بوتاسيوم الدم).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مصاباً بأمراض كبدية <strong>شديدة</strong> مع أمراض الكلى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شخصاً ما في عائلتك لديه تاريخ من اضطرابات &nbsp;نظْم القلب ( اضطراب نظْم &nbsp;القلب البطيني، بما في ذلك حالة تورساد دي بوانت) أو شذوذ مخطط كهربائية القلب (خلل في رسم القلب والتسجيل الكهربائي للقلب) يسمى &quot;متلازمة&nbsp;كيو تي الطويلة &quot;.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تتناول أدوية تسمى تيكاغريلور أو رانولازين (للنوبة القلبية أو لألم الصدر أو الذبحة الصدرية).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تتناول الكولشيسين (عادة ما يؤخذ للنقرس)</p><p dir="RTL"><strong>التحذيرات والاحتياطات:</strong></p><p dir="RTL">تحدث مع طبيبك أو الصيدلي قبل تناول أقراص كلاسيد في الحالات التالية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مشاكل في القلب (مثل أمراض القلب أو قصور القلب أو بطء في معدل ضربات القلب بشكل غير عادي أو الانخفاض غير الطبيعي لمستويات المغنيسيوم في الدم (نقص ماغنسيوم الدم))</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك أي مشاكل في الكبد أو الكلى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك، أو عرضة للإصابة بالعدوى الفطرية (على سبيل المثال القلاع)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ حاملاً أو في مرحلة الرضاعة الطبيعية</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أقراص كلاسيد غير مناسبة للأطفال أصغر من سن 12 عام.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإستخدام مع الأدوية الأخرى:</strong></p><p dir="RTL">ينبغي <strong>ألا</strong> تتناول أقراص كلاسيد إن كنت تتناول أيّاً من الأدوية المبينة في القسم المذكور أعلاه &quot;لا تتناول أقراص كلاسيد إذا كنت؛&quot;</p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول، أو تناولت مؤخراً أو قد تتناول مستقبلاً أي أدوية أخرى، حيث قد تكون هناك حاجة إلى تغيير جرعة كلاسيد التي تتناولها أو إجراء بعض الفحوصات بانتظام:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ديجوكسين أو كويندين أو ديسوبيراميد (لعلاج مشكلات القلب).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إبروتينيب (لعلاج السرطان)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وارفارين أو أي من مضادات التجلط الأخرى ( لسيولة الدم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كاربامازيبين، ڤالبروات، فينوباربيتال أو &nbsp;فينيتوين (أدوية الصرع).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أتورفاستاتين، روسوفاستاتين (مثبطات&nbsp;مختزلة الإنزيم HMG-CoA المعروفة على نحو شائع باسم الستاتينات، والتي تُستخدم لخفض مستويات الكولسترول (نوع من الدهون) في الدم). الستاتينات يمكنها أن تسبب انحلال العضلات المخططـة الهيكليـة (الحالة التي يحدث فيها انهيار الأنسجة العضلية والتي يمكن أن تؤدي إلى تلف الكلى) ومن ثم ينبغي مراقبة أعراض الاعتلال العضلي (آلام العضلات أو ضعف العضلات).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ناتيجلينيد، بيوجليتازون، ريباجلينيد، روزيجليتازون أو الأنسولين (التي تستخدم لخفض مستويات الجلوكوز في الدم).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; غليكلازيد أو غليميبيريد (أدوية السلفونيل يوريا المستخدمة في علاج النوع الثاني من مرض السكري)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ثيوفيلين (يُستخدم في علاج المرضى المصابين بصعوبات تنفسية مثل الربو).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ترايازولام، &nbsp;ألبرازولام، ميدازولام المُستخدم عبر الغشاء المخاطي الفموي أو عن طريق الوريد (مهدئ).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيلوستازول (لعلاج قصور&nbsp;الدورة الدموية).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الميثادون (المستخدم في علاج إدمان المواد الأفيونية).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ميثيل بردنيزولون (كورتيكوستيرويد).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ڤينبلاستين (لعلاج السرطان).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيكلوسبورين، سيروليميس، تاكروليمس (مثبطات المناعة).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إترافيرين، إيفافيرنز، نيفيرابين، ريتونافير، زيدوفودين، أتازانافير، ساكوينافير (الأدوية المضادة للفيروسات المستخدمة في علاج فيروس نقص المناعة البشرية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ريفابيوتين، ريفامبيسين، ريفابنتين، فلوكانازول، أيتراكونازول (تُستخدم في علاج بعض أنواع العدوى البكتيرية).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تولتيرودين (لعلاج فرط&nbsp;نشاط المثانة).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فيراباميل، أملوديبين، ديلتيازيم (لارتفاع ضغط الدم).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيلدينافيل، فاردينافيل، تادالافيل (لعلاج العجز الجنسي عند الذكور البالغين أو للاستخدام في ارتفاع ضغط الدم الشرياني الرئوي (ارتفاع ضغط الدم في الأوعية الدموية في الرئة)).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عشبة سانت جون (منتج عشبي يُستخدم لعلاج الاكتئاب).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;كويتيابين أو الأدوية الأخرى المضادة للذهان.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية الماكروليدية الأخرى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لينكوميسين وكليندامايسين (من مجموعة اللينكوساميدات &nbsp;- نوع من المضادات الحيوية)</p><p dir="RTL">يرجى إخبار طبيبك إذا تعرّضت&nbsp; للإسهال &nbsp;أو القيء أثناء تناولك حبوب منع الحمل، حيث قد تحتاجين إلى اتخاذ احتياطات إضافية لمنع الحمل مثل استخدام الواقي الذكري</p><p dir="RTL"><strong>الحمل والرضاعة:</strong></p><p>إذا كنت حاملاً،&nbsp;أو ترضعين طفلك رضاعة طبيعية أو تعتقدين أنك قد تكونين حاملاً، أو تخططين للحمل، فيجب استشارة طبيبكِ أو الصيدلي قبل تناول هذا الدواء حيث إن سلامة استخدام أقراص كلاسيد في الحمل والرضاعة غير معروفة.</p><p dir="RTL"><strong>القيادة وإستخدام الآلات:</strong></p><p>قد تجعلك أقراص كلاسيد تشعر بالدوار أو النعاس. إذا كان هذا الدواء يؤثر عليك بهذه الطريقة، فيجب عليك أن تتجنّب القيادة أو تشغيل الآلات أو القيام بعمل يتطلب منك ان تكون في حالة انتباه.</p><p>&nbsp;</p><p>تحتوي أقراص كلاسيد على أقل من 1 مليمول من الصوديوم (23 مجم) لكل جرعة، أي &quot;خالٍ من الصوديوم&quot; بشكل أساسي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>لا تعطِ هذه الأقراص للأطفال دون سن 12 عاماً. وسوف يصف الطبيب الدواء المناسب لطفلك.</p><p>يجب تناول جرعة كلاسيد كما يصفها الطبيب بدقة. يجب عليك أن تستشير طبيبك أو الصيدلى إذا كنت غير متأكد من الجرعة، الجرعة الموصوفة لك</p><p>الجرعة هي:</p><p><strong>لعلاج لعدوى الصدر، &nbsp;الحلق أو الجيوب الأنفية وعدوى الجلد والأنسجة الرّخوة: </strong>الجرعة المعتادة من أقراص كلاسيد للبالغين والأطفال فوق 12 سنة هي 250 ملغم مرتين يومياً&nbsp;صباحاً ومساءاً لمدة 6 إلى 14 يوما. وقد يحتاج طبيبك لزيادة الجرعة إلى 500 ملغم مرتين يومياً في العدوى الشديدة. يجب ابتلاع الأقراص مع ما لا يقل عن نصف كوب ماء.</p><p><strong>لعلاج عدوى الملوية البوابية</strong><strong> والمرتبطة بقرحة الاثني عشر:</strong></p><p>هناك عدد من مجموعات العلاج الفعالة المتاحة لعلاج الملوية البوابية<strong> </strong>حيث يتم تناول<strong> أقراص كلاسيد مع واحد أو اثنين من الأدوية الأخرى:</strong></p><p>وتشمل هذه المجموعات ما يلي، وعادة ما تؤخذ لمدة 6 إلى 14 يوما:</p><p dir="RTL">أ&zwnj;-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قرص واحد كلاسيد 500 ملغم مرتين يومياً + أموكساسيلين &nbsp;1000 ملغم &nbsp;مرتين يومياً + لانزوبرازول 30 ملغم مرتين يومياً.</p><p dir="RTL">ب&zwnj;-&nbsp;&nbsp;&nbsp;&nbsp; قرص واحد كلاسيد 500 ملغم مرتين يومياً + ميترونيدازول 400 ملغم &nbsp;مرتين يومياً+ لانزوبرازول 30 ملغم مرتين يومياً.</p><p dir="RTL">ت&zwnj;-&nbsp;&nbsp;&nbsp;&nbsp; قرص واحد كلاسيد 500 ملغم مرتين يومياً + أموكساسيلين 1000 ملغم مرتين يومياً + ميترونيدازول 400 ملغم مرتين يومياً + أوميبرازول 40 ملغم مرة واحدة يومياً.</p><p>قرص واحد كلاسيد 500 ملغم مرتين يومياً + أموكساسيلين 1000 ملغم مرتين يومياً + أوميبرازول 20 ملغم مرة واحدة يومياً</p><p dir="RTL">قد تختلف تركيبة العلاج التي تتلقاها قليلاً عما سبق. سيقرر طبيبك تركيبة العلاج الأنسب لك. إذا لم تكن متأكدًا من الأقراص التي يجب أن تتناولها أو لكم من الوقت يجب أن تتناولها ، فيرجى استشارة طبيبك للحصول على المشورة.</p><p dir="RTL"><strong>إذا تناولت جرعة زائدة من أقراص كلاسيد:</strong></p><p>إذا تناولت أكثر من الجرعة المقررة من أقراص كلاسيد بطريق الخطأ في يوم واحد، أو إذا ابتلع الطفل بعض الأقراص بطريق الخطأ، فاتصل بالطبيب أو بأقرب مستشفى أو قسم طوارئ عَلى الفور حيث قد تتسبب الجرعة الزائدة من أقراص كلاسيد في التقيؤ وآلام في المعدة.</p><p>&nbsp;</p><p dir="RTL"><strong>إذا نسيت أن تتناول أقراص كلاسيد</strong><strong>:</strong></p><p>إذا نسيت أن تتناول جرعة من أقراص كلاسيد، فيمكنك تناولها في أقرب وقت تتذكرها. لا تتناول أكثر من الجرعة التي وصفها لك الطبيب في يوم واحد.</p><p>&nbsp;</p><p dir="RTL"><strong>التوقف عن تناول كلاسيد:</strong></p><p>لا تتوقف عن تناول أقراص كلاسيد، حتى لو كنت تشعر بتحسن ومن المهم أن تتناول الأقراص على مدار المدة التي حددها لك الطبيب، وإلا فإن المرض قد يعود مرة أخرى.</p><p>&nbsp;</p><p>إذا كان لديك أي أسئلة أخرى حول استخدام هذا الدواء، فاسأل طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل جميع الأدوية، يمكن أن تسبب أقراص كلاسيد بعض الآثار الجانبية على الرغم من عدم حدوث ذلك لكل الأشخاص.</p><p>إذا كنت تعاني من أي من الأعراض التالية في أي وقت أثناء العلاج، فيجب التوقف عن تناول الأقراص والاتصال بالطبيب على الفور.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإسهال الشديد أو الإسهال لفترات طويلة، والذي قد يكون مختلطاً به دم أو مخاط. قد يحدث الإسهال على مدى أكثر من شهرين بعد العلاج بالكلاريثرومايسين وإذا حدث ذلك، يجب الاتصال بالطبيب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي، أو صعوبة التنفس، أو الإغماء، أو تورم الوجه أو اللسان أو الشفتين أو العينين أو الحلق. وهذه علامة على احتمال إصابتك برد فعل تحسسي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اصفرار الجلد (اليرقان)، أو تهيج الجلد، أو البراز فاتح اللون، أو البول غامق اللون، أو إيلام البطن عند لمسها، أو فقدان الشهية. وتلك علامات على أن كبدك قد يكون مصاباً بالالتهاب وأنه قد لا يؤدي وظيفته بشكل سليم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات جلدية شديدة مثل تقرحات مؤلمة في الجلد والفم والعينين والشفتين والأعضاء التناسلية، (أعراض لتفاعل حساسية نادر يسمى متلازمة ستيفنز جونسون/ تقشر الأنسجة المتموتة البشروية التسممي).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي أحمر ومتقشر، مع تحاديب تحت الجلد وبثور (أعراض البثار الطفحي). معدّل تكرار هذا الأثر الجانبي مجهول (أي لا يمكن تقدير ه من خلال البيانات المتاحة).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تحدث بشكل نادر تفاعلات حساسية حادة بالجلد تسبب مرضاً شديداً مصحوباً بتقرّح الفم والشفتين والجلد، مما يسبب مرضاً شديداً يصاحبه طفح جلدي وحمى والتهاب الأعضاء الداخلية (متلازمة DRESS).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم أو ضعف في العضلات يُعرف باسم انحلال العضلات المخططـة الهيكليـة &nbsp;(وهي حالة تتسبب في انهيار الأنسجة العضلية والتي يمكن أن تؤدي إلى تلف الكلى).</p><p dir="RTL"><strong>آثار جانبية أخرى</strong></p><p dir="RTL">الآثار الجانبية الشائعة (قد تؤثر على ما يصل إلى 1 من أصل 10 أشخاص) وتشمل:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة النوم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التغيرات في حاسة التذوق</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اتساع الأوعية الدموية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل في المعدة مثل الشعور بالإعياء، والتقيؤ، وآلام في المعدة، وعسر الهضم، والإسهال</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة التعرق</p><p dir="RTL">الآثار الجانبية غير الشائعة (قد تؤثر على ما يصل إلى 1 من أصل 100 شخص) وتشمل:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع درجة الحرارة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم، احمرار أو حكة في الجلد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى فطرية بالفم أو المهبل (القلاع)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب المعدة والأمعاء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستويات الصفائح الدموية (الصفائح الدموية تساعد على وقف النزيف)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض في عدد خلايا الدم البيضاء (نقص الكريات البيض)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض في تعداد الكريات البيض المعتدلة (نقص العدلات)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التصلب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القشعريرة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة الحمضات (ارتفاع مستوى الكريات البيضاء الحمِضة المساعدة في المناعة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة الاستجابة المناعية للأجسام الغريبة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نقص الشهية أو فقدانها</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القلق والعصبية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نعاس، تعب، دوخة أو رعشة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حركات لا إرادية بالعضلات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدوار</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رنين في الأذنين أو فقدان السمع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في الصدر أو تغيرات في إيقاع نبض القلب مثل الخفقان أو اضطراب نظْم القلب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الربو: أمراض الرئة المرتبطة بضيق الممرات الهوائية، مما يجعل التنفس صعباً</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف الأنف</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تجلط الدم الذي يسبب انسداداً مفاجئاً في شريان الرئة (الانصمام الرئوي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب بطانة المريء وبطانة المعدة &nbsp;ألم بالشرج</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الانتفاخ والإمساك وخروج الغازات من البطن والتجشؤ</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جفاف الفم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ركود الصفراء (السوائل التي يفرزها الكبد وتخزن في المرارة) وفي هذه الحالة لا يمكن أن تتدفق الصفراء من المرارة إلى الاثني عشر (الركود الصفراوي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الجلد الذي يتميز بوجود فقاعات مليئة بالسوائل، وبالطفح الجلدي المؤلم والمثير للحكة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تشنجات العضلات، آلام في العضلات أو فقدان الأنسجة العضلية. إذا كان طفلك يعاني من الوهن العضلي الوبيل (وهي حالة تصبح فيها العضلات ضعيفة ويصيبها التعب بسهولة)، فقد يؤدي كلاريثرومايسين إلى تفاقم هذه الأعراض</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نتائج مرتفعة وغير طبيعية لاختبارات الدم لوظائف الكلى والكبد وغيرها من اختبارات الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالضعف والتعب وفقدان الطاقة</p><p dir="RTL">الآثار الجانبية غير المعروفة (لا يمكن تقدير معدل تكرارها من البيانات المتاحة):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب القولون</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى بكتيرية في الطبقات الخارجية من الجلد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستوى بعض خلايا الدم (التي يمكن أن تزيد من احتمالية الإصابة بالعدوى أو تزيد من خطر الكدمات أو النزيف)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الارتباك، وفقدان إدراك الاتجاهات، والهلوسة (رؤية أشياء غير حقيقية)، وتغيير الشعور بالواقع أو الفزع، والاكتئاب، والأحلام غير الطبيعية أو الكوابيس والهوس (الشعور بالابتهاج والانتشاء أو الإثارة المفرطة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التشنج (نوبات)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التنميل، وغالباً ما يتم الشعور به على هيئة إحساس بوخذ الدبابيس والإبر</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان حاسة التذوق أو الشم أو عدم القدرة على الشم بشكل صحيح</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوع من اضطراب نظْم القلب (تورساد دي بوانت، تسرع&nbsp;القلب&nbsp;البطيني)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الدم (النزف)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب البنكرياس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغير لون اللسان أو الأسنان</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حب الشباب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغير في مستويات إفرازات الكلى، التهاب الكلى أو عدم قدرة الكلى على العمل بشكل صحيح (قد تلاحظ شعور بالتعب، وتتعرّض للتورم أو الانتفاخ في الوجه والبطن والفخذين أو الكاحلين أو مشكلات في التبول)</p><p>الإبلاغ عن الأعراض الجانبية</p><p dir="RTL">إذا أُصبت بأي من هذه الأعراض الجانبية، فأبلغ الطبيب المعالج أو الصيدلي. وهذا يشمل أي آثار جانبية محتملة غير مدرجة في هذه النشرة. بالإبلاغ عن الآثار الجانبية، يمكنك المساعدة في توفير مزيد من المعلومات حول أمان هذا الدواء.</p><p dir="RTL"><strong>للإبلاغ عن الأعراض الجانبية</strong></p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>المركز الوطني للتيقظ والسلامة الدوائية (</strong><strong>NPC</strong><strong>)</strong></p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فاكس 7662-205-11-966+</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مركز الاتصال: 19999</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الموقع الإلكتروني: https://ade.sfda.gov.sa</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحفظ بعيدا عن متناول ومرأى &nbsp;الأطفال.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فترة الصلاحية: 3 سنوات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستخدم هذه الأقراص بعد تاريخ انتهاء الصلاحية المطبوع على الشريط والعلبة الخارجية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحفظ في درجة حرارة أقل من 25 درجة مئوية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تحفظ هذه الأقراص في مكان جاف وآمن ومحمية من الضوء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا ينبغي أن يتم التخلص من الأدوية في مياه الصرف الصحي أو عن طريق النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد مطلوبة. هذه التدابير تساعد في الحفاظ على البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>محتوى عبوة أقراص كلاسيد. </strong>يحتوي كل قرص من كلاسيد على المادة الفعالة كلاريثروميسين بتركيز 250 ملغم.</p><p>المكوّنات الأخرى غير الفعّالة هي: الكينولون الأصفر (E104)، كروسكارملوز الصوديوم، السليلوز دقيق التبلور ، ثاني أكسيد السيليكون ، البوفيدون ، حامض ستياريك ، ستيرات المغنيسيوم ، التلك ، هيدروكسي بروبيلين جليكول ، سوربيتان أحادي الأولييت ، ثاني أكسيد التيتانيوم ، فانيلين، هيدروكسي بروبيل السيللوز ، وحمض السوربيك</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ما هو شكل كلاسيد ومحتويات العلبة؟</strong></p><p dir="RTL">أقراص كلاسيد 250 ملغم عبارة عن أقراص صفراء، بيضاوية ملساء أو مع علامة &quot;a&quot;.</p><p dir="RTL">تتوافر أقراص كلاسيد 250 ملغم في شرائط مطبوع عليها تقويم تحتوي على 14قرص.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>صاحب حق التسويق:</strong></p><p dir="RTL">أبوب لابوراتوريز GmbH، هانوفر، ألمانيا</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>المصنع:</strong></p><p dir="RTL">أبفي إس أر إل إل-04011 كومبيفردي أبريليا، إيطاليا</p><p dir="RTL"><strong>تم التغليف في:</strong></p><p dir="RTL">مصنع الرياض فارما للصناعات الدوائية ومستحضرات التجميل</p><p dir="RTL">الرياض، المملكة العربية السعودية</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            مايو 2021
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Klacid 250 mg Tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                One tablet contains 250 mg clarithromycin.

Excipient with known effect: sodium 3.4 mg per tablet For a full list of excipients, see section 6.1

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                A yellow, ovaloid film-coated tablet containing 250 mg of clarithromycin, plain or embossed with Abbott logo.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Consideration should be given to official guidance on the appropriate use of antibacterial agents.</p><p>&nbsp;</p><p>Klacid 250mg Tablets are indicated in adults and children 12 years and older.</p><p>&nbsp;</p><p>Clarithromycin is indicated for treatment of infections caused by susceptible organisms. &nbsp;Indications include:</p><p>&nbsp;</p><p>Lower respiratory tract infections for example, acute and chronic bronchitis, and pneumonia (see section 4.4 and 5.1 regarding Sensitivity Testing).</p><p>&nbsp;</p><p>Upper respiratory tract infections for example, sinusitis and pharyngitis.</p><p>Clarithromycin is appropriate for initial therapy in community acquired respiratory infections and has been shown to be active <em>in vitro </em>against common and atypical respiratory pathogens as listed in the microbiology section.</p><p>&nbsp;</p><p>Clarithromycin is also indicated in skin and soft tissue infections of mild to moderate severity (e.g. folliculitis, cellulitis, erysipelas) (see section 4.4 and</p><p>5.1 regarding Sensitivity Testing).</p><p>&nbsp;</p><p>Clarithromycin in the presence of acid suppression effected by omeprazole or lansoprazole is also indicated for the eradication of <em>H. pylori </em>in patients with duodenal ulcers. See Dosage and Administration section.</p><p>Clarithromycin is usually active against the following organisms in vitro: Gram-positive Bacteria:&nbsp; &nbsp;<em>Staphylococcus aureus </em>(methicillin susceptible);</p><p><em>Streptococcus pyogenes </em>(Group A beta-haemolytic streptococci); alpha- haemolytic streptococci (viridans group<em>); Streptococcus</em><em> (Diplococcus) pneumoniae; Streptococcus agalactiae; Listeria monocytogenes</em>.</p><p>&nbsp;</p><p>Gram-negative Bacteria: &nbsp;<em>Haemophilus influenzae; Haemophilus parainfluenzae; Moraxella (Branhamella) catarrhalis; Neisseria gonorrhoeae; Legionella pneumophila; Bordetella pertussis; Helicobacter pylori; Campylobacter jejuni.</em></p><p><em>&nbsp;</em></p><p>Mycoplasma: <em>Mycoplasma pneumoniae;</em><em> </em><em>Ureaplasma urealyticum.</em></p><p><em>&nbsp;</em></p><p>Other Organisms: <em>Chlamydia</em><em> trachomatis; Mycobacterium avium; Mycobacterium leprae.</em></p><p><em>&nbsp;</em></p><p>Anaerobes:&nbsp; Macrolide-<em>susceptible Bacteroides</em><em> fragilis; Clostridium perfringens</em>; Peptococcus species; Peptostreptococcus species; <em>Propionibacterium acnes</em>.</p><p>&nbsp;</p><p>Clarithromycin has bactericidal activity against several bacterial strains. The organisms include <em>Haemophilus influenzae; Streptococcus pneumoniae;</em><em> Streptococcus pyogenes; Streptococcus agalactiae; Moraxella (Branhamella) catarrhalis; Neisseria gonorrhoeae; H. pylori </em>and Campylobacter spp.</p><p>&nbsp;</p><p>The activity of clarithromycin against <em>H. pylori </em>is greater at neutral pH than at acid pH.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Patients with respiratory tract/skin and soft tissue infections.</u></p><p>&nbsp;</p><p>Adults: The usual dose is 250 mg twice daily although this may be increased to 500mg twice daily in severe infections. The usual duration of treatment is 6 to 14 days.</p><p>Children older than 12 years: As for adults.</p><p>&nbsp;</p><p>Children younger than 12 years:</p><p>Use of Klacid 500mg Tablets are not recommended for children younger &nbsp;than 12 years. Clinical trials have been conducted using clarithromycin paediatric suspension in children 6 months to 12 years of age. Therefore, children under 12 years of age should use clarithromycin paediatric suspension (granules for oral suspension).</p><p>Clarithromycin may be given without regard to meals as food does not affect the extent of bioavailability.</p><p>&nbsp;</p><p><u>Eradication of <em>H. pylori </em>in patients with duodenal ulcers (Adults)</u> The usual duration of treatment is 6 to 14 days.</p><p>&nbsp;</p><p>Triple Therapy</p><p>Clarithromycin (500mg) twice daily and lansoprazole 30mg twice daily should be given with amoxycillin 1000mg twice daily.</p><p>&nbsp;</p><p>Triple Therapy</p><p>Clarithromycin (500mg) twice daily and lansoprazole 30mg twice daily should be given with metronidazole 400mg twice daily.</p><p>&nbsp;</p><p>Triple Therapy</p><p>Clarithromycin (500mg) twice daily and omeprazole 40mg daily should be given with amoxycillin 1000mg twice daily or metronidazole 400mg twice daily.</p><p>Triple Therapy</p><p>Clarithromycin (500mg) twice daily and omeprazole 20mg daily should be given with amoxycillin 1000mg twice daily.</p><p>Elderly: As for adults. Renal impairment:</p><p>In patients with renal impairment with creatinine clearance less than</p><p>30 mL/min, the dosage of clarithromycin should be reduced by one-half, <em>i.e</em>. 250 mg once daily, or 250 mg twice daily in more severe infections. Treatment should not be continued beyond 14 days in these patients.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to macrolide antibiotic drugs or to any of the excipients listed in section 6.1.

Concomitant administration of clarithromycin and ergot alkaloids (e.g., ergotamine or dihydroergotamine) is contraindicated, as this may result in ergot toxicity (see section 4.5).
Concomitant administration of clarithromycin and oral midazolam is contraindicated (see section 4.5).

Concomitant administration of clarithromycin and any of the following drugs is contraindicated: astemizole, cisapride, domperidone, pimozide and terfenadine as this may result in QT prolongation and cardiac arrhythmias, including ventricular tachycardia, ventricular fibrillation, and torsades de pointes (see section 4.4 and 4.5).

Clarithromycin should not be given to patients with history of QT prolongation (congenital or documented acquired QT prolongation) or ventricular cardiac arrhythmia, including torsades de pointes (see sections 4.4 and 4.5).

Concomitant administration with ticagrelor or ranolazine is contraindicated.

Clarithromycin should not be used concomitantly with HMG-CoA reductase inhibitors (statins) that are extensively metabolized by CYP3A4, (lovastatin or simvastatin), due to the increased risk of myopathy, including rhabdomyolysis. (See section 4.5).

As with other strong CYP3A4 inhibitors, Clarithromycin should not be used in patients taking colchicine (see sections 4.4 and 4.5).

Clarithromycin should not be given to patients with hypokalaemia (risk of prolongation of QT-time).

Clarithromycin should not be used in patients who suffer from severe hepatic failure in combination with renal impairment.



            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Use of any antimicrobial therapy, such as clarithromycin, to treat <em>H. pylori</em></p><p>infection may select for drug-resistant organisms.</p><p>&nbsp;</p><p>The physician should not prescribe clarithromycin to pregnant women without carefully weighing the benefits against risk, particularly during the first three months of pregnancy (see section 4.6).</p><p>&nbsp;</p><p>Clarithromycin is principally metabolised by the liver. &nbsp;Therefore, caution should be exercised in administering this antibiotic to patients with impaired hepatic function.</p><p>&nbsp;</p><p>Caution should also be exercised when administering clarithromycin to patients with moderate to severe renal impairment (see section 4.2).</p><p>&nbsp;</p><p>Hepatic dysfunction, including increased liver enzymes, and hepatocellular and/or cholestatic hepatitis, with or without jaundice, has been reported with</p><p>clarithromycin. This hepatic dysfunction may be severe and is usually reversible. Cases of fatal hepatic failure (see section 4.8) have been reported. Some patients may have had pre-existing hepatic disease or may have been taking other hepatotoxic medicinal products. Patients should be advised to stop treatment and contact their doctor if signs and symptoms of hepatic disease develop, such as anorexia, jaundice, dark urine, pruritus, or tender abdomen.</p><p>&nbsp;</p><p>Pseudomembranous colitis has been reported with nearly all antibacterial agents, including macrolides, and may range in severity from mild to life- threatening. Clostridium difficile- associated diarrhoea (CDAD) has been reported with use of nearly all antibacterial agents including clarithromycin, and may range in severity from mild diarrhoea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon, which may lead to overgrowth of C. difficile. CDAD must be considered in all patients who present with diarrhoea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents. Therefore, discontinuation of clarithromycin therapy should be considered regardless of the indication.</p><p>Microbial testing should be performed and adequate treatment initiated. Drugs inhibiting peristalsis should be avoided.</p><p>&nbsp;</p><p>There have been post-marketing reports of colchicine toxicity with concomitant use of clarithromycin and colchicine, especially in the elderly, some of which occurred in patients with renal insufficiency. Deaths have been reported in some such patients (see section 4.5). Concomitant administration of clarithromycin and colchicine is contraindicated (see section 4.3).</p><p>&nbsp;</p><p>Caution is advised regarding concomitant administration of clarithromycin and triazolobenzodiazepines, such as triazolam, and intravenous or oromucosal midazolam (see section 4.5).</p><p><u>Cardiovascular</u><u> Events:</u></p><p>&nbsp;</p><p>Prolongation of the QT interval, reflecting effects on cardiac repolarisation imparting a risk of developing cardiac arrhythmia and <em>torsades de pointes</em>, have been seen in &nbsp;patients treated with macrolides including clarithromycin (see section 4.8). Due to increased risk of QT prolongation and ventricular arrhythmias (including <em>torsades de pointes</em>), the use of clarithromycin is contraindicated: in patients taking any of astemizole, cisapride, domperidone, pimozide and terfenadine; in patients who have hypokalaemia; and in patients with a history of QT prolongation or ventricular cardiac arrhythmia (see section 4.3).</p><p>Furthermore, clarithromycin should be used with caution in the following:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patients with coronary artery disease, severe cardiac insufficiency, conduction disturbances or clinically relevant bradycardia;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patients with hypomagnesaemia;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patients concomitantly taking other medicinal products associated with QT prolongation other than those which are contraindicated</p><p>&nbsp;</p><p>Epidemiological studies investigating the risk of adverse cardiovascular outcomes with macrolides have shown variable results. Some observational studies have identified a rare short-term risk of arrhythmia, myocardial infarction and cardiovascular mortality associated with macrolides including clarithromycin. Consideration of these findings should be balanced with treatment benefits when prescribing clarithromycin.</p><p>&nbsp;</p><p>Pneumonia: In view of the emerging resistance of Streptococcus pneumoniae to macrolides, it is important that sensitivity testing be performed when prescribing clarithromycin for community-acquired pneumonia. In hospital- acquired pneumonia, clarithromycin should be used in combination with additional appropriate antibiotics.</p><p>&nbsp;</p><p>Skin and soft tissue infections of mild to moderate severity: These infections are most often caused by Staphylococcus aureus and Streptococcus pyogenes, both of which may be resistant to macrolides. Therefore, it is important that sensitivity testing be performed. In cases where beta&ndash;lactam antibiotics cannot be used (e.g. allergy), other antibiotics, such as clindamycin, may be the drug of first choice. Currently, macrolides are only considered to play a role in some skin and soft tissue infections, such as those caused by Corynebacterium minutissimum, acne vulgaris, and erysipelas and in situations where penicillin treatment cannot be used.</p><p>In the event of severe acute hypersensitivity reactions, such as anaphylaxis, severe cutaneous adverse reactions (SCAR) (e.g. Acute generalised exanthematous pustulosis (AGEP), Stevens-Johnson Syndrome, toxic epidermal necrolysis and drug rash with eosinophilia and systemic symptoms (DRESS)), clarithromycin therapy should be discontinued immediately and appropriate treatment should be urgently initiated.</p><p>&nbsp;</p><p>Clarithromycin should be used with caution when administered concurrently with medications that induce the cytochrome CYP3A4 enzyme (see section 4.5).</p><p>&nbsp;</p><p>HMG-CoA Reductase Inhibitors (statins): Concomitant use of clarithromycin with lovastatin or simvastatin is contraindicated (see section 4.3). Caution should be exercised when prescribing clarithromycin with other statins.</p><p>Rhabdomyolysis has been reported in patients taking clarithromycin and statins. Patients should be monitored for signs and symptoms of myopathy.</p><p>&nbsp;</p><p>In situations where the concomitant use of clarithromycin with statins cannot be avoided, it is recommended to prescribe the lowest registered dose of the statin. Use of a statin that is not dependent on CYP3A metabolism (e.g. fluvastatin) can be considered (see 4.5).</p><p>&nbsp;</p><p>Oral hypoglycaemic agents/Insulin: The concomitant use of clarithromycin and oral hypoglycaemic agents (such as sulphonylauriad) and/or insulin can&nbsp;</p><p>result in significant hypoglycaemia. Careful monitoring of glucose is recommended (see section 4.5).</p><p>&nbsp;</p><p>Oral anticoagulants: There is a risk of serious haemorrhage and significant elevations in International Normalized Ratio (INR) and prothrombin time when clarithromycin is co-administered with warfarin (see section 4.5). INR and prothrombin times should be frequently monitored while patients are receiving clarithromycin and oral anticoagulants concurrently.</p><p>&nbsp;</p><p>Long-term use may, as with other antibiotics, result in colonisation with increased numbers of non-susceptible bacteria and fungi. If superinfections occur, appropriate therapy should be instituted.</p><p>&nbsp;</p><p>Attention should also be paid to the possibility of cross resistance between clarithromycin and other macrolide drugs, as well as lincomycin and clindamycin.</p><p>&nbsp;</p><p><u>Excipients</u></p><p>This medicine contains less than 1 mmol sodium (23 mg) per dosage unit, that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>The</strong><strong> use of the following drugs is strictly contraindicated due to the potential for severe drug interaction effects:</strong></p><p><u>Astemizole,</u><u> cisapride, domperidone, pimozide, and terfenadine:</u></p><p>Elevated cisapride levels have been reported in patients receiving clarithromycin and cisapride concomitantly. This may result in QT prolongation and cardiac arrhythmias including ventricular tachycardia, ventricular fibrillation and torsades de pointes.</p><p>Similar effects have been observed in patients taking clarithromycin and pimozide concomitantly (see section 4.3).</p><p>Macrolides have been reported to alter the metabolism of terfenadine resulting in increased levels of terfenadine which has occasionally been associated with cardiac arrhythmias, such as QT prolongation, ventricular tachycardia, ventricular fibrillation and torsades de pointes (see section 4.3). In one study in 14 healthy volunteers, the concomitant administration of clarithromycin and terfenadine resulted in 2- to 3-fold increase in the serum level of the acid metabolite of terfenadine and in prolongation of the QT interval which did not lead to any clinically detectable effect. Similar effects have been observed with concomitant administration of astemizole and other macrolides.</p><p><u>Ergot</u><u> alkaloids:</u></p><p>Post-marketing reports indicate that co-administration of clarithromycin with ergotamine or dihydroergotamine has been associated with acute ergot toxicity characterized by vasospasm, and ischaemia of the extremities and other tissues including the central nervous system. Concomitant administration of clarithromycin and ergot alkaloids is contraindicated (see section 4.3).</p><p><u>Oral</u><u> </u><u>Midazolam</u></p><p>&nbsp;</p><p>When midazolam was co-administered with clarithromycin tablets (500 mg twice daily), midazolam AUC was increased 7-fold after oral administration of midazolam. Concomitant administration of oral midazolam and clarithromycin is contraindicated (see section 4.3).</p><p><u>HMG-CoA</u><u> Reductase Inhibitors (statins)</u></p><p>Concomitant use of clarithromycin with lovastatin or simvastatin is contraindicated (see 4.3) as these statins are extensively metabolized by CYP3A4 and concomitant treatment with clarithromycin increases their plasma concentration, which increases the risk of myopathy, including rhabdomyolysis. Reports of rhabdomyolysis have been received for patients taking clarithromycin concomitantly with these statins. If treatment with clarithromycin cannot be avoided, therapy with lovastatin or simvastatin must be suspended during the course of treatment.</p><p>Caution should be exercised when prescribing clarithromycin with statins. In situations where the concomitant use of clarithromycin with statins cannot be avoided, it is recommended to prescribe the lowest registered dose of the statin. Use of a statin that is not dependent on CYP3A metabolism (e.g. fluvastatin) can be considered. Patients should be monitored for signs and symptoms of myopathy.</p><p><strong><em><u>Effects</u></em></strong><strong><em><u> </u></em></strong><strong><em><u>of Other Medicinal Products on Clarithromycin</u></em></strong></p><p>Drugs that are inducers of CYP3A (e.g. rifampicin, phenytoin, carbamazepine, phenobarbital, St John&rsquo;s wort) may induce the metabolism of clarithromycin. This may result in sub-therapeutic levels of clarithromycin leading to reduced efficacy. Furthermore, it might be necessary to monitor the plasma levels of the CYP3A inducer, which could be increased owing to the inhibition of CYP3A by clarithromycin (see also the relevant product information for the CYP3A4 inducer administered). Concomitant administration of rifabutin and clarithromycin resulted in an increase in rifabutin, and decrease in clarithromycin serum levels together with an increased risk of uveitis.</p><p>The following drugs are known or suspected to affect circulating concentrations of clarithromycin; clarithromycin dosage adjustment or consideration of alternative treatments may be required.</p><p><u>Efavirenz,</u><u> nevirapine, rifampicin, rifabutin and rifapentine</u></p><p>Strong inducers of the cytochrome P450 metabolism system such as efavirenz, nevirapine, rifampicin, rifabutin, and rifapentine may accelerate the metabolism of clarithromycin and thus lower the plasma levels of clarithromycin, while increasing those of 14-OH-clarithromycin, a metabolite that is also microbiologically active. Since the microbiological activities of clarithromycin and 14-OH-clarithromycin are different for different bacteria, the intended therapeutic effect could be impaired during concomitant administration of clarithromycin and enzyme inducers.</p><p><u>Etravirine</u></p><p>Clarithromycin exposure was decreased by etravirine; however, concentrations of the active metabolite, 14-OH-clarithromycin, were increased. Because 14-OH- clarithromycin has reduced activity against Mycobacterium avium complex (MAC), overall activity against this pathogen may be altered; therefore alternatives to clarithromycin should be considered for the treatment of MAC.</p><p><u>Fluconazole</u></p><p>Concomitant administration of fluconazole 200 mg daily and clarithromycin 500 mg twice daily to 21 healthy volunteers led to increases in the mean steady-state minimum clarithromycin concentration (Cmin) and area under the curve (AUC) of 33% and 18% respectively. Steady state concentrations of the active metabolite 14-&nbsp;OH-clarithromycin were not significantly affected by concomitant administration of fluconazole. No clarithromycin dose adjustment is necessary.</p><p><u>Ritonavir</u></p><p>A pharmacokinetic study demonstrated that the concomitant administration of ritonavir 200 mg every eight hours and clarithromycin 500 mg every 12 hours resulted in a marked inhibition of the metabolism of clarithromycin. The clarithromy&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cin Cmax increased by 31%, Cmin increased 182% and AUC increased by &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;77% with concomitant administration of ritonavir. An essentially complete inhibition of the formation of 14-OH-clarithromycin was noted. Because of the large therapeutic window for clarithromycin, no dosage reduction should be necessary in patien&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ts with normal renal function. However, for patients with renal impairment, the following dosage adjustments should be considered: For patients with CLCR 30 to 60 mL/min the dose of clarithromycin should be reduced by 50%. For patients with CLCR</p><p>&lt;30 mL/min the dose of clarithromycin should be decreased by 75%. Doses of clarithromycin greater than 1 g/day should not be co-administered with ritonavir.</p><p>Similar dose adjustments should be considered in patients with reduced renal function when ritonavir is used as a pharmacokinetic enhancer with other HIV protease inhibitors including atazanavir and saquinavir (see section below, Bi-directional drug interactions).</p><p><strong><em><u>Effect</u></em></strong><strong><em><u> </u></em></strong><strong><em><u>of</u></em></strong><strong><em><u> </u></em></strong><strong><em><u>Clarithromycin </u></em></strong><strong><em><u>on</u></em></strong><strong><em><u> </u></em></strong><strong><em><u>Other</u></em></strong><strong><em><u> </u></em></strong><strong><em><u>Medicinal</u></em></strong><strong><em><u> </u></em></strong><strong><em><u>Products</u></em></strong></p><p><u>CYP3A-based</u><u> interactions</u></p><p>Co-administration of clarithromycin, which is known to inhibit CYP3A, and a drug primarily metabolised by CYP3A may be associated with elevations in drug concentrations that could increase or prolong both therapeutic and adverse effects of the concomitant drug.</p><p>The use of clarithromycin is contraindicated in patients receiving the CYP3A substrates astemizole, cisapride, domperidone, pimozide and terfenadine due to the risk of QT prolongation and cardiac arrhythmias, including ventricular tachycardia, ventricular fibrillation, and torsades de pointes (see sections 4.3 and 4.4).</p><p>The use of clarithromycin is also contraindicated with ergot alkaloids, oral midazolam, HMG CoA reductase inhibitors metabolised mainly by CYP3A4 (e.g. lovastatin and simvastatin), colchicine, ticagrelor and ranolazine (see section 4.3).</p><p>Caution is required if clarithromycin is co-administered with other drugs known to be CYP3A enzyme substrates, especially if the CYP3A substrate has a narrow safety margin (e.g. carbamazepine) and/or the substrate is extensively metabolised by this enzyme. Dosage adjustments may be considered, and when possible, serum concentrations of drugs primarily metabolised by CYP3A should be monitored closely in patients concurrently receiving clarithromycin. Drugs or drug classes that are known or suspected to be metabolised by the same CYP3A isozyme include (but this list is not comprehensive) alprazolam, carbamazepine, cilostazole, ciclosporin, disopyramide, ibrutinib, methadone, methylprednisolone, midazolam (intravenous), omeprazole, oral anticoagulants (e.g. warfarin), atypical antipsychotics (e.g. quetiapine), quinidine, rifabutin, sildenafil, sirolimus, tacrolimus, triazolam and vinblastine.</p><p>Drugs interacting by similar mechanisms through other isozymes within the cytochrome P450 system include phenytoin, theophylline and valproate.</p><p><u>Antiarrhythmics</u></p><p>There have been post-marketed reports of torsades de pointes occurring with the concurrent use of clarithromycin and quinidine or disopyramide. Electrocardiograms&nbsp;</p><p>should be monitored for QT prolongation during co-administration of clarithromycin with these drugs. Serum levels of quinidine and disopyramide should be monitored during clarithromycin therapy.</p><p>There have been post marketing reports of hypoglycemia with the concomitant administration of clarithromycin and disopyramide. Therefore blood glucose levels should be monitored during concomitant administration of clarithromycin and disopyramide.</p><p><u>Oral hypoglycemic agents/Insulin</u></p><p>With certain hypoglycemic drugs such as nateglinide, and repaglinide, inhibition of CYP3A enzyme by clarithromycin may be involved and could cause hypoglycaemia when used concomitantly. Careful monitoring of glucose is recommended.</p><p><u>Omeprazole</u></p><p>Clarithromycin (500 mg every 8 hours) was given in combination with omeprazole (40 mg daily) to healthy adult subjects. The steady-state plasma concentrations of omeprazole were increased (Cmax, AUC0-24, and t1/2&nbsp;increased by 30%, 89%, and 34%, respectively), by the concomitant administration of clarithromycin. The mean 24-hour gastric pH value was 5.2 when omeprazole was administered alone and 5.7 when omeprazole was co-administered with clarithromycin.</p><p><u>Sildenafil,</u><u> tadalafil and vardenafil</u></p><p>Each of these phosphodiesterase inhibitors is metabolised, at least in part, by CYP3A, and CYP3A may be inhibited by concomitantly administered clarithromycin. Co- administration of clarithromycin with sildenafil, tadalafil or vardenafil would likely result in increased phosphodiesterase inhibitor exposure. Reduction of sildenafil, tadalafil and vardenafil dosages should be considered when these drugs are co- administered with clarithromycin.</p><p><u>Theophylline,</u><u> </u><u>carbamazepine</u></p><p>Results of clinical studies indicate that there was a modest but statistically significant</p><p>(p&nbsp;&le; &nbsp;0.05) increase of circulating theophylline or carbamazepine levels when either of</p><p>&nbsp;</p><p>these drugs were administered concomitantly with clarithromycin. Dose reduction may need to be considered.</p><p><u>Tolterodine</u></p><p>The primary route of metabolism for tolterodine is via the 2D6 isoform of cytochrome P450 (CYP2D6). However, in a subset of the population devoid of CYP2D6, the identified pathway of metabolism is via CYP3A. In this population subset, inhibition of CYP3A results in significantly higher serum concentrations of tolterodine. A reduction in tolterodine dosage may be necessary in the presence of CYP3A inhibitors, such as clarithromycin in the CYP2D6 poor metaboliser population.</p><p><u>Triazolobenzodiazepines</u><u> (e.g., alprazolam, midazolam, triazolam)</u></p><p>When midazolam was co-administered with clarithromycin tablets (500 mg twice daily), midazolam AUC was increased 2.7-fold after intravenous administration of midazolam. If intravenous midazolam is co-administered with clarithromycin, the patient must be closely monitored to allow dose adjustment. Drug delivery of midazolam via oromucosal route, which could bypass pre-systemic elimination of the drug, will likely result in a similar interaction to that observed after intravenous midazolam rather than oral administration. The same precautions should also apply to other benzodiazepines that are metabolised by CYP3A, including triazolam and alprazolam. For benzodiazepines which are not dependent on CYP3A for their&nbsp;</p><p>elimination (temazepam, nitrazepam, lorazepam), a clinically important interaction with clarithromycin is unlikely.</p><p>There have been post-marketing reports of drug interactions and central nervous system (CNS) effects (e.g., somnolence and confusion) with the concomitant use of clarithromycin and triazolam. Monitoring the patient for increased CNS pharmacological effects is suggested.</p><p><strong><em><u>Other</u></em></strong><strong><em><u> drug interactions</u></em></strong></p><p><u>Colchicine</u></p><p>Colchicine is a substrate for both CYP3A and the efflux transporter, P-glycoprotein (Pgp). Clarithromycin and other macrolides are known to inhibit CYP3A and Pgp. When clarithromycin and colchicine are administered together, inhibition of Pgp and/or CYP3A by clarithromycin may lead to increased exposure to colchicine (see section 4.3 and 4.4).</p><p><em><u>Digoxin</u></em></p><p>Digoxin is thought to be a substrate for the efflux transporter, P-glycoprotein (Pgp). Clarithromycin is known to inhibit Pgp. When clarithromycin and digoxin are administered together, inhibition of Pgp by clarithromycin may lead to increased exposure to digoxin. Elevated digoxin serum concentrations in patients receiving clarithromycin and digoxin concomitantly have also been reported in post marketing surveillance. Some patients have shown clinical signs consistent with digoxin toxicity, including potentially fatal arrhythmias. Serum digoxin concentrations should be carefully monitored while patients are receiving digoxin and clarithromycin simultaneously.</p><p><u>Zidovudine</u></p><p>Simultaneous oral administration of clarithromycin tablets and zidovudine to HIV- infected adult patients may result in decreased steady-state zidovudine concentrations. Because clarithromycin appears to interfere with the absorption of simultaneously administered oral zidovudine, this interaction can be largely avoided by staggering the doses of clarithromycin and zidovudine to allow for a 4-hour interval between each medication. This interaction does not appear to occur in paediatric HIV-infected patients taking clarithromycin suspension with zidovudine or dideoxyinosine. This interaction is unlikely when clarithromycin is administered via intravenous infusion.</p><p><u>Phenytoin</u><u> </u><u>and Valproate</u></p><p>There have been spontaneous or published reports of interactions of CYP3A inhibitors, including clarithromycin with drugs not thought to be metabolised by CYP3A (e.g. phenytoin and valproate). Serum level determinations are recommended for these drugs when administered concomitantly with clarithromycin. Increased serum levels have been reported.</p><p><strong><em><u>Bi-directional</u></em></strong><strong><em><u> </u></em></strong><strong><em><u>drug interactions</u></em></strong></p><p><u>Atazanavir</u></p><p>Both clarithromycin and atazanavir are substrates and inhibitors of CYP3A, and there is evidence of a bi-directional drug interaction. Co-administration of clarithromycin (500 mg twice daily) with atazanavir (400 mg once daily) resulted in a 2-fold increase in exposure to clarithromycin and a 70% decrease in exposure to 14-OH- clarithromycin, with a 28% increase in the AUC of atazanavir. Because of the large therapeutic window for clarithromycin, no dosage reduction should be necessary in patients with normal renal function. For patients with moderate renal function (creatinine clearance 30 to 60 mL/min), the dose of clarithromycin should be decreased by 50%. For patients with creatinine clearance &lt;30 mL/min, the dose of&nbsp;</p><p>clarithromycin should be decreased by 75% using an appropriate clarithromycin formulation. Doses of clarithromycin greater than 1000 mg per day should not be co- administered with protease inhibitors.</p><p><u>Calcium</u><u> </u><u>Channel</u><u> Blockers</u></p><p>Caution is advised regarding the concomitant administration of clarithromycin and calcium channel blockers metabolized by CYP3A4 (e.g. verapamil, amlodipine, diltiazem) due to the risk of hypotension. Plasma concentrations of clarithromycin as well as calcium channel blockers may increase due to the interaction. Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients taking clarithromycin and verapamil concomitantly.</p><p><u>Itraconazole</u></p><p>Both clarithromycin and itraconazole are substrates and inhibitors of CYP3A, leading to a bidirectional drug interaction. Clarithromycin may increase the plasma levels of itraconazole, while itraconazole may increase the plasma levels of clarithromycin.</p><p>Patients taking itraconazole and clarithromycin concomitantly should be monitored closely for signs or symptoms of increased or prolonged pharmacologic effect.</p><p><u>Saquinavir</u></p><p>Both clarithromycin and saquinavir are substrates and inhibitors of CYP3A, and there is evidence of a bi-directional drug interaction. Concomitant administration of clarithromycin (500 mg twice daily) and saquinavir (soft gelatin capsules, 1200 mg three times daily) to 12 healthy volunteers resulted in steady-state AUC and Cmax&nbsp;values of saquinavir which were 177% and 187% higher than those seen with saquinavir alone. Clarithromycin AUC and Cmax&nbsp;values were approximately 40% higher than those seen with clarithromycin alone. No dose adjustment is required when the two drugs are co-administered for a limited time at the doses/formulations studied. Observations from drug interaction studies using the soft gelatin capsule formulation may not be representative of the effects seen using the saquinavir hard gelatin capsule. Observations from drug interaction studies performed with saquinavir alone may not be representative of the effects seen with saquinavir/ritonavir therapy. When saquinavir is co-administered with ritonavir, consideration should be given to the potential effects of ritonavir on clarithromycin (see section 4.5: Ritonavir).</p><p>Patients taking oral contraceptives should be warned that if diarrhoea, vomiting or breakthrough bleeding occur there is a possibility of contraceptive failure.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy</p><p>The safety of clarithromycin for use during pregnancy has not been established.</p><p>Based on variable results obtained from studies in mice, rats, rabbits and monkeys, the possibility of adverse effects on embryofoetal development cannot be excluded.</p><p>Therefore, use during pregnancy is not advised without carefully weighing the benefits against risk (see section 5.3).</p><p>&nbsp;</p><p>Breast-feeding</p><p>The safety of clarithromycin for using during breast-feeding of infants has not been established. Clarithromycin is excreted into human breast milk.</p><p>Fertility</p><p>In the rat, fertility studies have not shown any evidence of harmful effects (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There are no data on the effect of clarithromycin on the ability to drive or use machines.&nbsp; The potential for dizziness, vertigo, confusion and disorientation, which may occur with the&nbsp; &nbsp;medication, should be taken into account before patients drive or use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>a.&nbsp; Summary of the safety profile</p><p><strong><em>&nbsp;</em></strong></p><p>The most frequent and common adverse reactions related to clarithromycin therapy &nbsp;for both adult and paediatric populations are abdominal pain, diarrhoea, nausea, vomiting and taste perversion. These adverse reactions are usually mild in intensity and are consistent with the known safety profile of macrolide antibiotics (see section b of section 4.8).</p><p>&nbsp;</p><p>There was no significant difference in the incidence of these gastrointestinal adverse reactions during clinical trials between the patient population with or without pre- existing mycobacterial infections.</p><p>a.&nbsp; Tabulated summary of adverse reactions</p><p><strong><em>&nbsp;</em></strong></p><p>The following table displays adverse reactions reported in clinical trials and from</p><p>post-marketing experience with clarithromycin immediate-release tablets, granules for oral suspension, powder for solution for injection, extended-release tablets and modified-release tablets.</p><p>&nbsp;</p><p>The reactions considered at least possibly related to clarithromycin are displayed by system organ class and frequency using the following convention: very common (&ge;1/10), common (&ge; 1/100 to &lt; 1/10), uncommon (&ge;1/1,000 to &lt; 1/100) and not known (adverse reactions from post-marketing experience; cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness when the seriousness could be assessed.</p><table border="1" cellspacing="1" cellpadding="1" style="width:672px"><tbody><tr><td style="text-align:center; width:149px">System Organ Class</td><td style="width:139px"><p style="text-align:center">Very common</p><p style="text-align:center">&ge;1/10</p></td><td style="width:87px"><p style="text-align:center">Common</p><p style="text-align:center">&ge; 1/100 to &lt; 1/10</p></td><td style="width:146px"><p style="text-align:center">Uncommon</p><p style="text-align:center">&ge;1/1,000 to &lt; 1/100</p></td><td style="text-align:center; width:149px">Not Known* (cannot be estimated from the available data)</td></tr><tr><td style="width:149px">Infections and infestations</td><td style="width:139px">&nbsp;</td><td style="width:87px">&nbsp;</td><td style="width:146px"><p>Cellulitis1,</p><p>candidiasis<strong>,</strong><strong> </strong>gastroenteritis2,</p><p>infection3, vaginal</p><p>infection</p></td><td style="width:149px">Pseudomembranous colitis, erysipelas,</td></tr><tr><td style="width:149px">Blood and lymphatic system</td><td style="width:139px">&nbsp;</td><td style="width:87px">&nbsp;</td><td style="width:146px">Leukopenia, neutropenia4, thrombocythaemia3, eosinophilia4</td><td style="width:149px">Agranulocytosis, thrombocytopenia</td></tr><tr><td style="width:149px">Immune system disorders</td><td style="width:139px">&nbsp;</td><td style="width:87px">&nbsp;</td><td style="width:146px">Anaphylactoid reaction1, hypersensitivity</td><td style="width:149px">Anaphylactic reaction. angioedema</td></tr><tr><td style="width:149px">Metabolism and nutrition disorders</td><td style="width:139px">&nbsp;</td><td style="width:87px">&nbsp;</td><td style="width:146px">Anorexia, decreased appetite</td><td style="width:149px">&nbsp;</td></tr><tr><td style="width:149px">Psychiatric disorders</td><td style="width:139px">&nbsp;</td><td style="width:87px">Insomnia</td><td style="width:146px">Anxiety, nervousness3,</td><td style="width:149px"><p>Psychotic disorder, confusional state5, depersonalisation, depression, disorientation,</p>hallucination, abnormal dreams, mania</td></tr><tr><td style="width:149px">Nervous system disorders</td><td style="width:139px">&nbsp;</td><td style="width:87px">Dysgeusia, headache</td><td style="width:146px">Loss of consciousness1, dyskinesia1, dizziness, somnolence5, tremor</td><td style="width:149px">Convulsion, ageusia, parosmia, anosmia, paraesthesia</td></tr><tr><td style="width:149px">Ear and labyrinth disorders</td><td style="width:139px">&nbsp;</td><td style="width:87px">&nbsp;</td><td style="width:146px">Vertigo, hearing impaired, tinnitus</td><td style="width:149px">Deafness</td></tr><tr><td style="width:149px">Cardiac disorders</td><td style="width:139px">&nbsp;</td><td style="width:87px">&nbsp;</td><td style="width:146px"><p>Cardiac arrest1,</p>atrial fibrillation1, electrocardiogram QT prolonged, extrasystoles1, palpitations</td><td style="width:149px">Torsades de pointes, ventricular tachycardia, ventricular fibrillation</td></tr><tr><td style="width:149px">Vascular disorders</td><td style="width:139px">&nbsp;</td><td style="width:87px">Vasodilation1</td><td style="width:146px">&nbsp;</td><td style="width:149px">Haemorrhage</td></tr><tr><td style="width:149px">Respiratory, thoracic and mediastinal disorder</td><td style="width:139px">&nbsp;</td><td style="width:87px">&nbsp;</td><td style="width:146px"><p>Asthma1, epistaxis2,</p>pulmonary embolism1</td><td style="width:149px">&nbsp;</td></tr><tr><td style="width:149px">Gastrointesti nal disorders</td><td style="width:139px">&nbsp;</td><td style="width:87px">Diarrhoea, vomiting, dyspepsia, nausea, abdominal pain</td><td style="width:146px"><p>Oesophagitis1,</p>gastrooesophageal reflux disease2, gastritis, proctalgia2, stomatitis, glossitis, abdominal distension4, constipation, dry mouth, eructation,&nbsp;flatulence,</td><td style="width:149px">Pancreatitis acute, tongue discolouration, tooth discolouration</td></tr><tr><td style="width:149px">Hepatobiliary disorders</td><td style="width:139px">&nbsp;</td><td style="width:87px">Liver function test abnormal</td><td style="width:146px">Cholestasis4, hepatitis4, alanine aminotransferase increased, aspartate aminotransferase increased, gamma- glutamyltransferase increased4</td><td style="width:149px">Hepatic failure, jaundice hepatocellular</td></tr><tr><td style="width:149px">Skin and subcutaneous tissue disorders</td><td style="width:139px">&nbsp;</td><td style="width:87px">Rash, hyperhidrosis</td><td style="width:146px">Dermatitis bullous1, pruritus, urticaria, rash maculo- papular3</td><td style="width:149px">Severe cutaneous adverse reactions (SCAR) (e.g. Acute generalised exanthematous pustulosis (AGEP),Stevens- Johnson syndrome, toxic epidermal necrolysis, drug rash with eosinophilia and systemic symptoms (DRESS)), acne</td></tr><tr><td style="width:149px">Musculoskeletal and connective tissue disorders</td><td style="width:139px">&nbsp;</td><td style="width:87px">&nbsp;</td><td style="width:146px">Muscle spasms3, musculoskeletal stiffness1, myalgia2</td><td style="width:149px">Rhabdomyolysis2,6, myopathy</td></tr><tr><td style="width:149px">Renal and urinary disorders</td><td style="width:139px">&nbsp;</td><td style="width:87px">&nbsp;</td><td style="width:146px">Blood creatinine increased1, blood urea increased1</td><td style="width:149px">Renal failure, nephritis interstitial</td></tr><tr><td style="width:149px">General disorders and administration site conditions</td><td style="width:139px">Injection site phlebitis1</td><td style="width:87px"><p>Injection site pain1, injection site inflammation</p>1</td><td style="width:146px">Malaise4, pyrexia3, asthenia, chest pain4, chills4, fatigue4</td><td style="width:149px">&nbsp;</td></tr><tr><td style="width:149px">Investigations</td><td style="width:139px">&nbsp;</td><td style="width:87px">&nbsp;</td><td style="width:146px"><p>Albumin globulin ratio abnormal1, blood alkaline phosphatase increased4,</p>blood lactate dehydrogenase increased4</td><td style="width:149px">International normalised ratio increased, prothrombin time prolonged, urine colour abnormal</td></tr></tbody></table><p>1 ADRs reported only for the Powder for Concentrate for Solution for Infusion formulation</p><p>2ADRs reported only for the Extended-Release Tablets formulation</p><p>3 ADRs reported only for the Granules for Oral Suspension formulation</p><p>4 ADRs reported only for the Immediate-Release Tablets formulation</p><p>5, 6 See section c)</p><p><em>* Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Patient exposure is estimated to be greater than 1 billion patient treatment days for clarithromycin.</em></p><p><em>&nbsp;</em></p><p>c.&nbsp; Description of selected adverse reactions</p><p><strong><em>&nbsp;</em></strong></p><p>Injection site phlebitis, injection site pain, and injection site inflammation are specific to the clarithromycin intravenous formulation.</p><p>&nbsp;</p><p>In some of the reports of rhabdomyolysis, clarithromycin was administered concomitantly with statins, fibrates, colchicine or allopurinol (see section 4.3 and 4.4).</p><p>&nbsp;</p><p>&nbsp;</p><p>There have been post-marketing reports of drug interactions and central nervous system (CNS) effects (e.g. somnolence and confusion) with the concomitant use of clarithromycin and triazolam.&nbsp; Monitoring the patient for increased CNS pharmacological effects is suggested (see section 4.5).</p><p>&nbsp;</p><p>There have been rare reports of clarithromycin ER tablets in the stool, many of which have occurred in patients with anatomic (including ileostomy or colostomy) or functional gastrointestinal disorders with shortened GI transit times. &nbsp;In several reports, tablet residues have occurred in the context of diarrhoea. &nbsp;It is recommended that patients who experience tablet residue in the stool and no improvement in their condition should be switched to a different clarithromycin formulation (e.g. suspension) or another antibiotic.</p><p>&nbsp;</p><p>Special population: Adverse Reactions in Immunocompromised Patients (see section e).</p><p>d.&nbsp;&nbsp;&nbsp; Paediatric populations</p><p><strong><em>&nbsp;</em></strong></p><p>Clinical trials have been conducted using clarithromycin paediatric suspension in children 6 months to 12 years of age. Therefore, children under 12 years of age should use clarithromycin paediatric suspension.</p><p>&nbsp;</p><p>Frequency, type and severity of adverse reactions in children are expected to be the same as in adults.</p><p>&nbsp;</p><p>e. Other special populations</p><p><strong><em>&nbsp;</em></strong></p><p><em>Immunocompromised patients</em></p><p><em>&nbsp;</em></p><p>In AIDS and other immunocompromised patients treated with the higher doses of clarithromycin over long periods of time for mycobacterial infections, it was often difficult to distinguish adverse events possibly associated with clarithromycin administration from underlying signs of Human Immunodeficiency Virus (HIV) disease or intercurrent illness.</p><p>In adult patients, the most frequently reported adverse reactions by patients treated with total daily doses of 1000 mg and 2000mg of clarithromycin were: nausea, vomiting, taste perversion, abdominal pain, diarrhoea, rash, flatulence, headache, constipation, hearing disturbance, <u>Serum Glutamic</u><u> Oxaloacetic Transaminase</u> (SGOT) and <u>Serum Glutamic Pyruvate Transaminase </u>(SGPT) elevations. Additional low-frequency events included dyspnoea, insomnia and dry mouth. The incidences were comparable for patients treated with 1000mg and 2000mg, but were generally about 3 to 4 times as frequent for those patients who received total daily doses of 4000mg of clarithromycin.</p><p>&nbsp;</p><p>In these immunocompromised patients, evaluations of laboratory values were made by analysing those values outside the seriously abnormal level (i.e. the extreme high or low limit) for the specified test. On the basis of these criteria, about 2% to 3% of those patients who received 1000mg or 2000mg of clarithromycin daily had seriously abnormal elevated levels of SGOT and SGPT, and abnormally low white blood cell and platelet counts. A lower percentage of patients in these two dosage groups also had elevated Blood Urea Nitrogen levels. Slightly higher incidences of abnormal values were noted for patients who received 4000mg daily for all parameters except White Blood Cell.</p><p>Reporting of suspected adverse reactions</p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions.</p><p><strong>To report any side effect(s):</strong></p><p>o <strong>-National Pharmacovigilance Center (NPC)</strong></p><p><strong>o Fax: +966-11-205-7662</strong></p><p><strong>o SFDA Call Center: 19999</strong></p><p><strong>o E-mail: npc.drug@sfda.gov.sa</strong></p><p><strong>o Website: https://ade.sfda.gov.sa</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Reports indicate that the ingestion of large amounts of clarithromycin can be expected to produce gastro-intestinal symptoms. One patient who had a history of bipolar disorder ingested 8 grams of clarithromycin and showed altered mental status, paranoid behaviour, hypokalaemia and hypoxaemia.</p><p>&nbsp;</p><p>Adverse reactions accompanying overdosage should be treated by the prompt elimination of unabsorbed drug and supportive measures. As with other macrolides, clarithromycin serum levels are not expected to be appreciably affected by haemodialysis or peritoneal dialysis.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>ATC Classification:</u></p><p>Pharmacotherapeutic group: Antibacterial for systemic use, macrolide ATC-Code: J01FA09</p><p>&nbsp;</p><p><u>Mechanism of action:</u></p><p>Clarithromycin is an antibiotic belonging to the macrolide antibiotic group. It exerts its antibacterial action by selectively binding to the 50s ribosomal sub- unit of susceptible bacteria preventing translocation of activated amino acids. It inhibits the intracellular protein synthesis of susceptible bacteria.</p><p>&nbsp;</p><p>The 14-hydroxy metabolite of clarithromycin, a product of parent drug metabolism also has antimicrobial activity.&nbsp; The metabolite is less active than the parent compound for most organisms, including mycobacterium spp. An exception is Haemophilus influenza where the 14-hydroxy metabolite is two- fold more active than the parent compound.</p><p>&nbsp;</p><p>Clarithromycin is usually active against the following organisms in vitro:-</p><p>&nbsp;</p><p><strong>Gram-positive Bacteria:</strong><strong> </strong><em>Staphylococcus aureus</em><em> </em><em>(</em>methicillin susceptible<em>);</em><em> Streptococcus pyogenes (</em>Group A beta-hemolytic streptococci<em>); alpha-</em><em> hemolytic streptococci (</em>viridans group<em>); Streptococcus</em><em> (</em>Diplococcus<em>)</em><em> pneumoniae; Streptococcus agalactiae; Listeria monocytogenes.</em></p><p><em>&nbsp;</em></p><p><strong>Gram-negative Bacteria: </strong><em>Haemophilus</em><em> influenzae; Haemophilus parainfluenzae;Moraxella </em>(Branhamella) <em>catarrhalis; Neisseria </em><em>gonorrhoeae;</em><em> </em><em>Legionella pneumophila; Bordetella</em><em> pertussis; Helicobacter pylori; Campylobacter jejuni.</em></p><p><em>&nbsp;</em></p><p><strong>Mycoplasma: </strong><em>Mycoplasma pneumoniae;</em><em> </em><em>Ureaplasma urealyticum.</em></p><p><em>&nbsp;</em></p><p><strong>Other Organisms: </strong><em>Chlamydia trachomatis;</em><em> Mycobacterium avium; Mycobacterium leprae.</em></p><p>&nbsp;</p><p><strong>Anaerobes: </strong>Macrolide-susceptible <em>Bacteroides</em><em> fragilis; Clostridium perfringens;</em></p><p><em>Peptococcus species;</em><em> </em><em>Peptostreptococcus species; Propionibacterium acnes.</em></p><p><em>&nbsp;</em></p><p>Clarithromycin has bactericidal activity against several bacterial strains. The organisms include <em>Haemophilus influenzae, Streptococcus pneumoniae,</em><em> Streptococcus pyogenes, Streptococcus agalactiae, Moraxella (</em>Branhamella<em>)</em><em> catarrhalis, Neisseria gonorrhoeae, H. pylori and Campylobacter spp</em>.</p><p>&nbsp;</p><p>Breakpoints</p><p>The following breakpoints have been established by the European Committee for Antimicrobial Susceptibility Testing (EUCAST).</p><p>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<strong> &nbsp;Breakpoints (MIC, mg/L)</strong></p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr></tr><tr><td style="text-align:center">Microorganism</td><td style="text-align:center">Susceptible (&le;)</td><td style="text-align:center">Resistant (&gt;)</td></tr><tr><td style="text-align:center"><em>Staphylococcus spp.</em></td><td style="text-align:center">1 mg/L</td><td style="text-align:center">2 mg/L</td></tr><tr><td style="text-align:center"><em>Streptococcus A, B, C and G</em></td><td style="text-align:center">0.25 mg/L</td><td style="text-align:center">0.5 mg/L</td></tr><tr><td style="text-align:center"><em>Streptococcus pneumonia</em></td><td style="text-align:center">0.25 mg/L</td><td style="text-align:center">0.5 mg/L</td></tr><tr><td style="text-align:center"><em>Viridans group streptococcus</em></td><td style="text-align:center">IE</td><td style="text-align:center">IE</td></tr><tr><td style="text-align:center"><em>Haemophilus spp.</em></td><td style="text-align:center">1 mg/L</td><td style="text-align:center">32 mg/L</td></tr><tr><td style="text-align:center"><em>Moraxella catarrhalis</em></td><td style="text-align:center">0.25 mg/L</td><td style="text-align:center">0.5 mg/L 1</td></tr><tr><td style="text-align:center"><em>Helicobacter pylori</em></td><td style="text-align:center">0.25 mg/L1</td><td style="text-align:center">0.5 mg/L</td></tr></tbody></table><p>1 The breakpoints are based on epidemiological cut-off values (ECOFFs), which distinguish&nbsp;</p><p>wild-type isolates from those with reduces susceptibility.</p><p>&ldquo;IE&quot; indicates that there is insufficient evidence that the species in question is a good target for therapy with the drug.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>H. pylori </em>is associated with acid peptic disease including duodenal ulcer and gastric ulcer in which about 95% and 80% of patients respectively are infected with the agent. <em>H. pylori </em>is also implicated as a major contribution factor in the development of gastric and ulcer recurrence in such patients.</p><p>&nbsp;</p><p>Clarithromycin has been used in small numbers of patients in other treatment regimens. Possible kinetic interactions have not been fully investigated. These regimens include:</p><p>&nbsp;</p><p>Clarithromycin plus tinidazole and omeprazole; clarithromycin plus tetracycline,</p><p>bismuth subsalicylate and ranitidine; clarithromycin plus ranitidine alone.</p><p>&nbsp;</p><p>Clinical studies using various different <em>H. pylori </em>eradication regimens have shown</p><p>that eradication of <em>H. pylori </em>prevents ulcer recurrence.</p><p>&nbsp;</p><p>Clarithromycin is rapidly and well absorbed from the gastro-intestinal tract after</p><p>oral administration of Clarithromycin tablets. The microbiologically active metabolite 14-hydroxyclarithromycin is formed by first pass metabolism. Clarithromycin may be given without regard to meals as food does not affect the extent of bioavailability of Clarithromycin tablets. Food does slightly delay the onset of absorption of clarithromycin and formation of the 14- hydroxymetabolite.</p><p>The pharmacokinetics of clarithromycin are non linear; however, steady-state is</p><p>attained within 2 days of dosing. At 250 mg b.i.d. 15-20% of unchanged drug is</p><p>excreted in the urine. With 500 mg b.i.d. daily dosing urinary excretion is greater</p><p>(approximately 36%). The 14-hydroxyclarithromycin is the major urinary metabolite and accounts for 10-15% of the dose. Most of the remainder of the dose is eliminated in the faeces, primarily via the bile. 5-10% of the parent drug</p><p>is recovered from the faeces.</p><p>&nbsp;</p><p>When clarithromycin 500 mg is given three times daily, the clarithromycin plasma concentrations are increased with respect to the 500 mg twice daily dosage.</p><p>&nbsp;</p><p>Clarithromycin provides tissue concentrations that are several times higher than the circulating drug levels. Increased levels have been found in both tonsillar and</p><p>lung tissue. Clarithromycin is 80% bound to plasma proteins at therapeutic levels.</p><p>&nbsp;</p><p>Clarithromycin also penetrates the gastric mucus. Levels of clarithromycin in gastric mucus and gastric tissue are higher when clarithromycin is co- administered with omeprazole than when clarithromycin is administered alone.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In acute mouse and rat studies, the median lethal dose was greater than the highest feasible dose for administration (5g/kg).</p><p>&nbsp;</p><p>In repeated dose studies, toxicity was related to dose, duration of treatment and species. Dogs were more sensitive than primates or rats. The major clinical signs at toxic doses included emesis, weakness, reduced food consumption and weight gain, salivation, dehydration and hyperactivity.&nbsp; In all species the liver was the primary target organ at toxic doses. Hepatotoxicity was detectable by early elevations of liver function tests.&nbsp; Discontinuation of the drug generally resulted in a return to or toward normal results.&nbsp; Other tissues less commonly affected included the stomach, thymus and other lymphoid tissues and the kidneys.&nbsp; At near therapeutic doses, conjunctival injection and lacrimation occurred only in dogs. At a massive dose of 400mg/kg/day, some dogs and monkeys developed corneal opacities and/or oedema.</p><p>&nbsp;</p><p><u>Fertility,</u><u> Reproduction and Teratogenicity</u></p><p>&nbsp;</p><p>Studies performed in rats at oral doses up to 500 mg/kg/day (highest dose associated with overt renal toxicity) demonstrated no evidence for clarithromycin-related adverse effects on male fertility. This dose corresponds to a human equivalent dose&nbsp;</p><p>(HED) of approximately 5 times the maximum recommended human dose (MRHD) on a mg/m2&nbsp;basis for a 60-kg individual.</p><p>Fertility and reproduction studies in female rats have shown that a daily dosage of 150 mg/kg/day (highest dose tested) caused no adverse effects on the oestrus cycle, fertility, parturition and number and viability of offspring. Oral teratogenicity studies in rats (Wistar and Spraque-Dawley), rabbits (New Zealand White) and cynomolgous monkeys failed to demonstrate any teratogenicity from clarithromycin at the highest doses tested up to 1.5, 2.4 and 1.5 times the MRHD on a mg/m2&nbsp;basis in the respective species.&nbsp; However, a similar study in Sprague-Dawley rats indicated a low (6%) incidence of cardiovascular abnormalities which appeared to be due to spontaneous expression of genetic changes. Two mouse studies revealed a variable incidence (3-30%) of cleft palate at ~5 times the MRHD on a mg/m2&nbsp;basis for a 60-kg individual.&nbsp; Embryonic loss was seen in monkeys but only at dose levels which were clearly toxic to the mothers.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Tablet Core Croscarmellose sodium Starch, pregelatinised Cellulose, microcrystalline</p><p>Quinoline Yellow (E104 aluminium lake) Silicon dioxide</p><p>Povidone Stearic acid</p><p>Magnesium stearate Talc</p><p>&nbsp;</p><p>Tablet Coating, Colour and Gloss Coating Hypromellose</p><p>Sorbitan oleate Propylene glycol Titanium dioxide Vanillin</p><p>Quinoline Yellow (E104 aluminium lake) Hydroxypropylcellulose</p><p>Sorbic acid</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>None known.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 25&deg;C.</p><p>Keep these tablets in a dry, safe place, protected from light.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>2/14/56 tablets in a blister original pack. The blisters are packaged in a carton with a pack insert.</p><p>&nbsp;</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements for disposal.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Abbott Laboratoreis Gmbh, Hannover, Germany
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                May 2021
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>